CLINDAMYCIN PHOSPHATE | N050537 | PFIZER INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Husch Blackwell, LLP FDA-2019-P-5403 · 8 docket documents Husch Blackwell LLP, on behalf of an unnamed client, filed a citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA designate ANDA No. 065049 (Clindamycin Phosphate Topical Solution USP, 1% (Pledgets)) by Perrigo New York, Inc. as a Reference Standa | 505(q) | 2019-11-15 | Withdrawn | Husch Blackwell, LLP |
Citizen Petition from Macleods Pharmaceuticals Limited FDA-2019-P-4481 · 8 docket documents Macleods Pharmaceuticals Limited submitted this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA designate the approved generic product ANDA #064050, Clindamycin phosphate topical solution 1% manufactured by Perrigo New York Inc., as a referen | Other | 2019-09-26 | Withdrawn | Macleods Pharmaceuticals Limited |
Citizen Petition from DuPont Pharmaceuticals FDA-1989-P-0176 · 4 docket documents Du Pont Pharmaceuticals submitted this citizen petition on January 25, 1989, requesting that the FDA Commissioner rule that an Abbreviated New Drug Application is acceptable for clindamycin phosphate injection USP at 150 mg/mL in 50 mL and 100 mL polyvinyl chloride containers. The petitioner argued | Other | 2017-07-17 | Withdrawn | DuPont Pharmaceuticals |
Citizen Petition from Guidelines, Inc. FDA-1992-P-0105 · 5 docket documents Guidelines, Inc. filed this petition under 21 USC 710(a) and 505(j)(2)(A) requesting that the FDA extend the List of Drug Products Suitable for Abbreviated New Drug Applications to include clindamycin phosphate topical lotion in a new dosage form consisting of individually packaged foil-covered satu | Other | 2017-07-11 | Withdrawn | Guidelines, Inc. |
Stiefel Laboratories, Inc. [Buchanan Ingersoll & Rooney] - Citizen Petition FDA-2009-P-0120 · 3 docket documents Stiefel Laboratories, Inc., through counsel at Buchanan Ingersoll & Rooney, filed this citizen petition under section 505(j) of the Federal Food, Drug and Cosmetic Act regarding Evoclin (clindamycin phosphate 1% topical aerosol foam), NDA 50-801, to request that FDA clarify and apply the 30-month st | 505(q) | 2009-03-04 | Denied | — |
Citizen Petition from E. Tanghetti, MD FDA-2006-P-0267 · 5 docket documents E. Tanghetti, MD, filed this petition on December 15, 2006, requesting that the FDA withdraw approval of and recall Ziana, a topical combination product containing clindamycin phosphate 1.2% and tretinoin 0.025%, or alternatively require long-term safety studies to evaluate antibiotic resistance ass | Other | 2008-11-15 | Denied | E. Tanghetti, MD |
Citizen Petition from Olsson, Frank And Weeda, P. C. FDA-2007-P-0059 · 5 docket documents Olsson, Frank and Weeda, P.C. filed this citizen petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting permission to submit an abbreviated new drug application for clindamycin phosphate foam in a non-aerosol, pump-dispensed dosage form differing from the referenc | Other | 2008-04-14 | Withdrawn | Olsson, Frank And Weeda, P. C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.